The Generalized Myasthenia Gravis market growth is driven by factors like increase in the prevalence of Generalized Myasthenia Gravis, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Generalized Myasthenia Gravis market report also offers comprehensive insights into the Generalized Myasthenia Gravis market size, share, Generalized Myasthenia Gravis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Generalized Myasthenia Gravis market size growth forward.
Some of the key highlights from the Generalized Myasthenia Gravis Market Insights Report:
- Several key pharmaceutical companies, including Biocon, Cartesian Therapeutics, UCB, Momenta Pharamaceuticals, HanAll Biopharma, Roche, Alexion, Novartis, Takeda, BioMarin, and others, are developing novel products to improve the Generalized Myasthenia Gravis treatment outlook.
- The total Generalized Myasthenia Gravis market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
- As per DelveInsight analysis, the Generalized Myasthenia Gravis market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Generalized Myasthenia Gravis Market Landscape
Generalized Myasthenia Gravis Overview
Generalized myasthenia gravis (GMG) is a neuromuscular transmission disorder that creates a fluctuating weakness of the voluntary muscles.
Myasthenia gravis (MG) is a disorder of neuromuscular transmission in which autoantibodies bind to acetylcholine receptors that are found in the postsynaptic membrane in the neuromuscular junction, making it difficult to transmit impulses to skeletal muscles and causing weakness. Its prevalence varies between 15 to 179 cases per million and the mortality rate varies between 0.06 to 0.89 per million person-years. This disease is characterized by fluctuating weakness of the voluntary muscles, which worsens with activity and as the day progresses. It is classified as generalized or as ocular.
Do you know the treatment paradigms for different countries? Download our Generalized Myasthenia Gravis Market Sample Report
Recent Breakthroughs in the Generalized Myasthenia Gravis Market
FDA Approves UCB Generalized Myasthenia Gravis Treatment: UCB’s rozanolixizumab-noli is approved for treatment of generalized myasthenia gravis in certain adult patient groups.
FDA announced approval of Rystiggo (rozanolixizumab-noli) as a treatment for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive on June 27, 2023. Rozanolixizumab-noli is a subcutaneous administered, humanized monoclonal antibody injection designed to accelerate the catabolism of antibodies and reduce the concentration of pathogenic immunoglobulin G (IgG) autoantibodies. The approval was granted to Union Chimique Belge (UCB), a Belgian biopharmaceuticals company.
Generalized Myasthenia Gravis Epidemiology Segmentation
DelveInsight’s Generalized Myasthenia Gravis market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Generalized Myasthenia Gravis historical patient pools and forecasted Generalized Myasthenia Gravis patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Generalized Myasthenia Gravis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Generalized Myasthenia Gravis Prevalence
- Age-Specific Generalized Myasthenia Gravis Prevalence
- Gender-Specific Generalized Myasthenia Gravis Prevalence
- Diagnosed and Treatable Cases of Generalized Myasthenia Gravis
Visit for more @ Generalized Myasthenia Gravis Epidemiological Insights
Generalized Myasthenia Gravis Treatment Market
The Generalized Myasthenia Gravis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Generalized Myasthenia Gravis market trends by analyzing the impact of current Generalized Myasthenia Gravis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Generalized Myasthenia Gravis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Generalized Myasthenia Gravis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Generalized Myasthenia Gravis market in 7MM is expected to witness a major change in the study period 2019-2032.
Generalized Myasthenia Gravis (gMG) Emerging Drugs
Nipocalimab: Prevention Bio
Momenta has developed nipocalimab (M281), a high affinity, fully human, aglycosylated, effectorless IgG1 anti-FcRn monoclonal antibody. In patients with gMG, nipocalimab is expected to improve nerve-to-muscle signals and muscle function, thus alleviating the clinical signs and symptoms of gMG. Nipocalimab has been granted Fast Track and Orphan Drug designation by the FDA in this indication.
Generalized Myasthenia Gravis Key Companies
- Biocon
- Cartesian Therapeutics
- UCB
- Momenta Pharamaceuticals
- HanAll Biopharma
- Roche
- Alexion
- Novartis
- Takeda
- BioMarin
For more information, visit Generalized Myasthenia Gravis Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Generalized Myasthenia Gravis Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Generalized Myasthenia Gravis, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Generalized Myasthenia Gravis epidemiology in the 7MM
- Generalized Myasthenia Gravis marketed and emerging therapies
- Generalized Myasthenia Gravis companies
- Generalized Myasthenia Gravis market drivers and barriers
Key Questions Answered in the Generalized Myasthenia Gravis Market Report 2032:
- What was the Generalized Myasthenia Gravis market share distribution in 2019, and how would it appear in 2032?
- What is the total Generalized Myasthenia Gravis market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Generalized Myasthenia Gravis market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Generalized Myasthenia Gravis market projected to expand at 7MM?
Table of Contents:
1 Generalized Myasthenia Gravis Market Key Comprehensive Insights
2 Generalized Myasthenia Gravis Market Report Introduction
3 Competitive Intelligence Analysis for Generalized Myasthenia Gravis
4 Generalized Myasthenia Gravis Market Analysis Overview at a Glance
5 Executive Summary of Generalized Myasthenia Gravis
6 Generalized Myasthenia Gravis Epidemiology and Market Methodology
7 Generalized Myasthenia Gravis Epidemiology and Patient Population
8 Generalized Myasthenia Gravis Patient Journey
9 Generalized Myasthenia Gravis Treatment Algorithm, Generalized Myasthenia Gravis Current Treatment, and Medical Practices
10 Key Endpoints in Generalized Myasthenia Gravis Clinical Trials
11 Generalized Myasthenia Gravis Marketed Therapies
12 Generalized Myasthenia Gravis Emerging Therapies
13 Generalized Myasthenia Gravis: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Generalized Myasthenia Gravis
16 Generalized Myasthenia Gravis Market Key Opinion Leaders Reviews
18 Generalized Myasthenia Gravis Market Drivers
19 Generalized Myasthenia Gravis Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Generalized Myasthenia Gravis Epidemiology 2032
DelveInsight's "Generalized Myasthenia Gravis - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Generalized Myasthenia Gravis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Generalized Myasthenia Gravis Pipeline 2023
"Generalized Myasthenia Gravis Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Generalized Myasthenia Gravis market. A detailed picture of the Generalized Myasthenia Gravis pipeline landscape is provided, which includes the disease overview and Generalized Myasthenia Gravis treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
